151. The effect of rhBMP-2 and PRP delivery by biodegradable β-tricalcium phosphate scaffolds on new bone formation in a non-through rabbit cranial defect model.
- Author
-
Lim HP, Mercado-Pagan AE, Yun KD, Kang SS, Choi TH, Bishop J, Koh JT, Maloney W, Lee KM, Yang YP, and Park SW
- Subjects
- Absorbable Implants, Animals, Bone Morphogenetic Protein 2 administration & dosage, Bone Regeneration drug effects, Drug Carriers chemical synthesis, Drug Carriers chemistry, Drug Delivery Systems instrumentation, Humans, Male, Models, Animal, Rabbits, Recombinant Proteins administration & dosage, Recombinant Proteins pharmacology, Skull pathology, Skull Fractures physiopathology, Skull Fractures therapy, Bone Morphogenetic Protein 2 pharmacology, Calcium Phosphates chemistry, Drug Delivery Systems methods, Osteogenesis drug effects, Platelet-Rich Plasma physiology, Skull injuries, Tissue Scaffolds chemistry
- Abstract
This study evaluated whether the combination of biodegradable β-tricalcium phosphate (β-TCP) scaffolds with recombinant human bone morphogenetic protein-2 (rhBMP-2) or platelet-rich plasma (PRP) could accelerate bone formation and increase bone height using a rabbit non-through cranial bone defect model. Four non-through cylindrical bone defects with a diameter of 8-mm were surgically created on the cranium of rabbits. β-TCP scaffolds in the presence and absence of impregnated rhBMP-2 or PRP were placed into the defects. At 8 and 16 weeks after implantation, samples were dissected and fixed for analysis by microcomputed tomography and histology. Only defects with rhBMP-2 impregnated β-TCP scaffolds showed significantly enhanced bone formation compared to non-impregnated β-TCP scaffolds (P < 0.05). Although new bone was higher than adjacent bone at 8 weeks after implantation, vertical bone augmentation was not observed at 16 weeks after implantation, probably due to scaffold resorption occurring concurrently with new bone formation.
- Published
- 2013
- Full Text
- View/download PDF